Despite well-documented improvement in attention deficit hyperactivity disorder (ADHD) in youths with the available single and combined pharmacologic agents, a number of youths remain with residual symptomatology causing impairment in multiple domains. Recent work has suggested a potential cognitive-enhancing role of cholinergic agents in ADHD. We describe five cases of ADHD youths aged 8-17 years being treated for ADHD with the acetylcholinesterase inhibitor donepezil (Aricept®), all of whom demonstrated improvement.
|Original language||English (US)|
|Number of pages||6|
|Journal||Journal of child and adolescent psychopharmacology|
|State||Published - 2000|